Virios Therapeutics Inc. [NASDAQ: VIRI] closed the trading session at $0.97 on 04/25/23. The day’s price range saw the stock hit a low of $0.772, while the highest price level was $1.44. The company report on April 24, 2023 at 4:15 PM that Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia.
-Virios’ IMC-1 Phase 3 Proposed Program is Considered Acceptable based on Initial FDA Feedback Pending Review of the Final Chronic Toxicology Program Results-.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
-Final Toxicology Results to be Submitted to FDA in May 2023-.
The stocks have a year to date performance of 311.02 percent and weekly performance of 57.60 percent. The stock has been moved at 214.94 percent over the last six months. The stock has performed 117.98 percent around the most recent 30 days and changed 193.23 percent over the most recent 3-months.
If compared to the average trading volume of 807.73K shares, VIRI reached to a volume of 111458157 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Virios Therapeutics Inc. [VIRI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VIRI shares is $2.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VIRI stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Virios Therapeutics Inc. is set at 0.14 The Price to Book ratio for the last quarter was 1.47, with the Price to Cash per share for the same quarter was set at 0.38.
VIRI stock trade performance evaluation
Virios Therapeutics Inc. [VIRI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 57.60. With this latest performance, VIRI shares gained by 117.98% in over the last four-week period, additionally plugging by 214.94% over the last 6 months – not to mention a drop of -76.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VIRI stock in for the last two-week period is set at 79.60, with the RSI for the last a single of trading hit 82.20, and the three-weeks RSI is set at 76.97 for Virios Therapeutics Inc. [VIRI]. The present Moving Average for the last 50 days of trading for this stock 0.4137, while it was recorded at 0.7294 for the last single week of trading, and 1.9334 for the last 200 days.
Virios Therapeutics Inc. [VIRI]: An insightful look at the core fundamentals
Return on Total Capital for VIRI is now -112.84, given the latest momentum, and Return on Invested Capital for the company is -112.22. Return on Equity for this stock declined to -112.22, with Return on Assets sitting at -101.45.
Reflecting on the efficiency of the workforce at the company, Virios Therapeutics Inc. [VIRI] managed to generate an average of -$3,061,958 per employee.Virios Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.00 and a Current Ratio set at 8.00.
Virios Therapeutics Inc. [VIRI]: Insider Ownership positions
There are presently around $1 million, or 17.00% of VIRI stock, in the hands of institutional investors. The top three institutional holders of VIRI stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 235,400, which is approximately 33.296% of the company’s market cap and around 12.05% of the total institutional ownership; WALLEYE CAPITAL LLC, holding 164,314 shares of the stock with an approximate value of $0.1 million in VIRI stocks shares; and WARBERG ASSET MANAGEMENT LLC, currently with $100000.0 in VIRI stock with ownership of nearly -20% of the company’s market capitalization.
Positions in Virios Therapeutics Inc. stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 14 institutional holders increased their position in Virios Therapeutics Inc. [NASDAQ:VIRI] by around 271,053 shares. Additionally, 9 investors decreased positions by around 290,131 shares, while 7 investors held positions by with 702,844 shares. The mentioned changes placed institutional holdings at 1,264,028 shares, according to the latest SEC report filing. VIRI stock had 5 new institutional investments in for a total of 65,883 shares, while 3 institutional investors sold positions of 81,998 shares during the same period.